<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052128</url>
  </required_header>
  <id_info>
    <org_study_id>ARN-AR18-CT-101</org_study_id>
    <nct_id>NCT02052128</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers</brief_title>
  <official_title>Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arno Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arno Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a&#xD;
      phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid&#xD;
      adenocarcinoma. Stage 1: Six dose cohorts, 5 using the extended release tablet (ER)&#xD;
      formulation (10 mg BID, 20 mg BID, 30 mg BID, 40 mg BID, 50 mg BID) and 1 using the&#xD;
      immediate-release (IR) tablet formulation 100 mg QD will be randomized in parallel. After&#xD;
      enrollment of 36 patients in Stage 1, a dose of 50 mg BID was determined to be the RP2D.&#xD;
      Stage 2: An additional 10 patients with recurrent or metastatic APRpos uterine endometrioid&#xD;
      adenocarcinoma (Stage 2a) will be enrolled at the RP2D. Based on the response in Stage 2a,&#xD;
      the cohort will be further expanded by up to 19 more patients to a total of 29 patients to&#xD;
      confirm the efficacy and safety profile of onapristone in this selected patient population&#xD;
      (Stage 2b).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: RP2D of a single agent extended-release tablet formulation of oral onapristone for future clinical development.</measure>
    <time_frame>Baseline to 57 days post-first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: ORR using RECIST 1.1 in 10-29 patients with recurrent or metastatic uterine endometrioid adenocarcinoma that is APRpos, and to determine the relationship between APR status and onapristone anti-tumor activity.</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of extended-release onapristone tablets BID and of immediate-release onapristone tablets QD</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
    <description>Safety will be assessed by physical exam, vital signs, monitoring of adverse events, changes in ECG, and other clinical laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of safety of extended-release BID vs. immediate release QD schedules</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
    <description>Safety will be assessed by physical exam, vital signs, monitoring of adverse events, changes in ECG, and other clinical laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity based on tumor assessments (RECIST 1.1) and dates of progression</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of onapristone, mono-demethylated onapristone and other metabolites in plasma and urine</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
    <description>AUC, Cmax, Tmax, t1/2</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy</condition>
  <arm_group>
    <arm_group_label>onapristone 10 mg BID mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 10 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 20 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 30 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 40 mg BID mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 40 mg BID mg extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 50 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 100 mg QD immediate-release tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onapristone</intervention_name>
    <arm_group_label>onapristone 10 mg BID mg</arm_group_label>
    <arm_group_label>onapristone 100 mg QD</arm_group_label>
    <arm_group_label>onapristone 20 mg BID</arm_group_label>
    <arm_group_label>onapristone 30 mg BID</arm_group_label>
    <arm_group_label>onapristone 40 mg BID mg</arm_group_label>
    <arm_group_label>onapristone 50 mg BID</arm_group_label>
    <other_name>ZK 98299</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Post- menopausal female patients, 18 years of age or greater.&#xD;
&#xD;
          2. In Stage 1, recurrent or metastatic PR-expressing cancer that has the potential to&#xD;
             benefit from an anti-progestin treatment including but not limited to endometrial&#xD;
             cancer, ovarian, or breast cancer or uterine sarcoma. In Stage 2, recurrent or&#xD;
             metastatic PR-expression uterine endometrioid adenocarcinoma that is determined to be&#xD;
             APRpos.&#xD;
&#xD;
          3. Patients who have metastatic or recurrent disease after previous surgery, radiation&#xD;
             therapy, and/or chemotherapy are eligible. In Stage 1, no restriction is placed on the&#xD;
             number of prior therapies. In Stage 2, patients may have 0 or 1 prior chemotherapy&#xD;
             treatments for adjuvant or metastatic disease and no prior endocrine therapies.&#xD;
&#xD;
          4. In Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease.&#xD;
&#xD;
          5. Appropriate archival OR current tissue blocks or biopsy specimens to determine ER/PR&#xD;
             and APR status.&#xD;
&#xD;
          6. Signed, written informed consent must be obtained and documented according to ICH-GCP,&#xD;
             the local regulatory requirements, and local data protection laws prior to&#xD;
             study-specific screening procedures.&#xD;
&#xD;
          7. ECOG performance status 0-1.&#xD;
&#xD;
          8. Health care coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Calculated creatinine clearance of &lt;60 mL/min in Stage 1 and &lt;40 mL/min in Stage 2&#xD;
&#xD;
          2. Patients with any other prior malignancy are not allowed except for the following:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               -  In situ cervical cancer&#xD;
&#xD;
               -  Adequately treated Stage I or II cancer from which the patient is currently in&#xD;
                  complete remission or other cancer from which the patient has been disease-free&#xD;
                  for 2 years&#xD;
&#xD;
          3. Body mass index (BMI) &lt;18.5 or &gt;35 kg/m2.&#xD;
&#xD;
          4. On ECG a QTc(F) interval &gt;480 msec or any clinically significant cardiac rhythm&#xD;
             abnormalities.&#xD;
&#xD;
          5. Liver function tests documented within the screening period and on day -1 of treatment&#xD;
             period:&#xD;
&#xD;
               -  Total bilirubin &gt; ULN (except in patients diagnosed with Gilbert's disease).&#xD;
&#xD;
               -  Alkaline phosphatase &gt; UNL or &gt; 2.5 x UNL in case of liver metastases, or &gt; 5 x&#xD;
                  UNL in case of bone metastases.&#xD;
&#xD;
               -  ALT/AST &gt; UNL or &gt; 2.5 x UNL in case of liver metastases.&#xD;
&#xD;
          6. Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2,&#xD;
             hepatitis B (surface antigen), or hepatitis C.&#xD;
&#xD;
          7. Chronic inflammatory liver condition.&#xD;
&#xD;
          8. Chronic adrenal failure or is receiving concurrent long-term corticosteroid therapy.&#xD;
&#xD;
          9. History or clinical evidence of any surgical or medical condition which the&#xD;
             investigator judges as likely to interfere with the results of the study or pose an&#xD;
             additional risk in participating.&#xD;
&#xD;
         10. Used any prescription medication during the prior 1 month that the investigator judges&#xD;
             is likely to interfere with the study or to pose an additional risk to the patient in&#xD;
             participating.&#xD;
&#xD;
         11. Received an investigational product or been treated with an investigational device&#xD;
             within 30 days prior to first drug administration, or plans to start any other&#xD;
             investigational product or device study within 30 days after last drug administration.&#xD;
&#xD;
         12. Received prior systemic anticancer treatment (chemotherapy, targeted therapies&#xD;
             including kinase inhibitors, antibodies, etc) less than 5 half-lives before the first&#xD;
             dose of study drug or radiotherapy within 30 days; toxicity of the anticancer&#xD;
             treatment must have recovered to grade 1 or less.&#xD;
&#xD;
         13. Current progestin-based hormone replacement therapy.&#xD;
&#xD;
         14. Lack of physical integrity of the upper gastrointestinal tract, malabsorption&#xD;
             syndrome, or inability to swallow pills.&#xD;
&#xD;
         15. Has a mental incapacity or language barriers precluding adequate understanding,&#xD;
             co-operation, and compliance with the study requirements.&#xD;
&#xD;
         16. Is, in the judgment of the investigator, unable or unwilling to comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
         17. Uncontrolled brain metastases or treatment by neurosurgical resection or brain biopsy&#xD;
             within 4 weeks prior to Day 1.&#xD;
&#xD;
         18. For Stage 2 only, mixed histology i.e. patients with &gt;10% non-endometrioid malignant&#xD;
             cells in provided histopathology samples.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul H Cottu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice S Bexon, MD</last_name>
    <phone>1-617-417-7300</phone>
    <email>alice.bexon@bexonclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Bonneterre, MD</last_name>
      <phone>[+33] (0)3.20.29.59.35</phone>
      <email>j-bonneterre@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul H Cottu, MD</last_name>
      <phone>[+33] (0)14 4324000</phone>
      <phone_ext>4670</phone_ext>
      <email>paul.cottu@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Varga, MD</last_name>
      <phone>[+33] (0)1 42 11 42 96</phone>
      <email>andrea.varga@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>uterine sarcoma</keyword>
  <keyword>uterine endometrioid adenocarcinoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onapristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

